Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

While vitamin D levels increased in both groups, the changes did not reach statistical significance by the end of the follow-up period.

Source: 3. Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study

Source: Article title.

All enrolled patients were capable of completing a 6-month follow-up.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study

Observational study · Viruses · 2025

Original publication title

Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study

Luca Rinaldi; Mauro Viganò; Alessia Ciancio; Alfredo Caturano; Vincenzo Messina; Grazia Anna Niro; Nicolina Capoluongo; Alessandro Loglio; Letizia Marinaro; Aldo Marrone; Ernesto Claar; Maurizio Russello; Emanuela Ciracì; Umberto Vespasiani Gentilucci; Valeria Pace Palitti; Carlo Acierno; Clelia Cosentino; Andrea Mormone; Rosa Cotugno; Francesca Terracciani; Paolo Gallo; Maria Rita Cannavò; Valerio Rosato; Ferdinando Carlo Sasso; Chiara Petrucciello; Giulio Petronio Petronio; Giovanni Villone; Francesco Benanti; Giuseppe Cariti; Elisabetta Falbo; Marco Distefano; Rodolfo Sacco; Alessandro Perrella; Antonio Izzi

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Introduction: Hepatitis D virus (HDV) infection remains a significant global health challenge due to its severity and high risk of progression to cirrhosis and hepatocellular carcinoma (HCC). Bulevirtide, a novel HDV entry inhibitor, has shown promise in managing chronic hepatitis D by blocking viral entry into hepatocytes. This study evaluated the efficacy and safety of bulevirtide in reducing HDV RNA levels and improving liver function in a real-life cohort of Italian patients with HDV infection. Methods: This multicenter prospective trial enrolled 108 consecutive patients with chronic HDV infection, from June 2023 to June 2024, who received 2 mg/day of bulevirtide in combination with a nucleoside/nucleotide analogue for hepatitis B virus (HBV) infection.

Patients with any stage of liver fibrosis or compensated cirrhosis were included. Data collected included demographic and clinical characteristics, liver function tests, HDV RNA levels, and adverse events at baseline and 6 months. Results: The virological response was achieved in 54.6% of patients (n = 59), with 36 demonstrating undetectable HDV RNA levels. Among responders, ALT levels decreased significantly from 67.0 U/mL [IQR 44.0 to 116.3] to 31.5 U/mL [IQR 24.0 to 36.5, p = 0.001], and AST levels from 66.0 U/mL [IQR 46.5 to 91.0] to 32.5 U/mL [IQR 28.0 to 38.0, p = 0.021].

Median HDV RNA dropped from 29,800 IU/mL [IQR 3100 to 375,000] to 0 IU/mL [IQR 0 to 291, p < 0.001]. No significant predictors of response emerged. Mild adverse events, including pruritus (5.6%) and injection-site reactions (1.9%) and flu-like syndrome (0.9) were reported, with no treatment discontinuation. Conclusions: Bulevirtide effectively reduces HDV RNA levels and improves liver function with a favorable safety profile, offering a promising therapeutic option for chronic hepatitis D. Further large-scale studies are needed to confirm these findings and explore long-term outcomes.

Authors’ abstract

Introduction: Hepatitis D virus (HDV) infection remains a significant global health challenge due to its severity and high risk of progression to cirrhosis and hepatocellular carcinoma (HCC). Bulevirtide, a novel HDV entry inhibitor, has shown promise in managing chronic hepatitis D by blocking viral entry into hepatocytes. This study evaluated the efficacy and safety of bulevirtide in reducing HDV RNA levels and improving liver function in a real-life cohort of Italian patients with HDV infection. Methods: This multicenter prospective trial enrolled 108 consecutive patients with chronic HDV infection, from June 2023 to June 2024, who received 2 mg/day of bulevirtide in combination with a nucleoside/nucleotide analogue for hepatitis B virus (HBV) infection.

Patients with any stage of liver fibrosis or compensated cirrhosis were included. Data collected included demographic and clinical characteristics, liver function tests, HDV RNA levels, and adverse events at baseline and 6 months. Results: The virological response was achieved in 54.6% of patients (n = 59), with 36 demonstrating undetectable HDV RNA levels. Among responders, ALT levels decreased significantly from 67.0 U/mL [IQR 44.0 to 116.3] to 31.5 U/mL [IQR 24.0 to 36.5, p = 0.001], and AST levels from 66.0 U/mL [IQR 46.5 to 91.0] to 32.5 U/mL [IQR 28.0 to 38.0, p = 0.021].

Median HDV RNA dropped from 29,800 IU/mL [IQR 3100 to 375,000] to 0 IU/mL [IQR 0 to 291, p < 0.001]. No significant predictors of response emerged. Mild adverse events, including pruritus (5.6%) and injection-site reactions (1.9%) and flu-like syndrome (0.9) were reported, with no treatment discontinuation. Conclusions: Bulevirtide effectively reduces HDV RNA levels and improves liver function with a favorable safety profile, offering a promising therapeutic option for chronic hepatitis D. Further large-scale studies are needed to confirm these findings and explore long-term outcomes.

Publication and source details

Original title: Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study

Luca Rinaldi; Mauro Viganò; Alessia Ciancio; Alfredo Caturano; Vincenzo Messina; Grazia Anna Niro; Nicolina Capoluongo; Alessandro Loglio; Letizia Marinaro; Aldo Marrone; Ernesto Claar; Maurizio Russello; Emanuela Ciracì; Umberto Vespasiani Gentilucci; Valeria Pace Palitti; Carlo Acierno; Clelia Cosentino; Andrea Mormone; Rosa Cotugno; Francesca Terracciani; Paolo Gallo; Maria Rita Cannavò; Valerio Rosato; Ferdinando Carlo Sasso; Chiara Petrucciello; Giulio Petronio Petronio; Giovanni Villone; Francesco Benanti; Giuseppe Cariti; Elisabetta Falbo; Marco Distefano; Rodolfo Sacco; Alessandro Perrella; Antonio Izzi

Viruses · 2025

* Correspondence: alfredo.caturano@unicampania.it© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).The authors received no financial support for the research, authorship, and/or publication of this article.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T06:44:53.246055+00:00

DOI: 10.3390/v17020251 · PMC11860205